This presentation is under embargo until 6 Feb 2026, as per congress regulations

Publication
  • EAHAD •
  • 4 February, 2026 •
  • •

Physical Activity and Efficacy in Patients with Severe Haemophilia A Treated with Efanesoctocog Alfa: 12-Month Interim Results from FREEDOM

Jan Astermark, Olga Benitez Hidalgo, Hervé Chambost, Antonio Coppola, Shamil Sadikhov, Jenny Björkqvist, Markus Fusser, Niamh O’Connell

Publication
  • EAHAD •
  • 4 February, 2026 •
  • •

Long-Term Clinical Outcomes of Efanesoctocog Alfa in Patients with Severe Haemophilia A: European Results from the Third Interim Analysis of XTEND-ed

Sophie Susen, Manuela Albisetti, Karin Fijnvandraat, Elena Santagostino, Mahnouch Georget, Meredith C. Foster, Pratima Chowdary

Publication
  • EAHAD •
  • 4 February, 2026 •
  • •

Treatment of Bleeding Episodes with Efanesoctocog Alfa in Adults, Adolescents, and Children with Severe Haemophilia A: Third Interim Analysis of the XTEND-ed Long-term Extension Study

Johannes Oldenburg, Manuel Carcao , Sandrine Meunier, Nobuaki Suzuki, María Teresa Álvarez Román, Graham Neill, Sriya Gunawardena, Lydia Abad-Franch, Meredith Foster, Linda Bystrická, Angela Weyand

Sign up for alerts